AGIO Agios Pharmaceuticals Inc.

-0.13  -0%
Previous Close 97.51
Open 97.58
Price To Book 6.48
Market Cap 5609635373
Shares 57,605,621
Volume 399,030
Short Ratio 14.29
Av. Daily Volume 352,344

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial to be initiated 4Q 2018.
NDA filing announced December 26, 2017.
IDH1m Relapsed/Refractory AML - cancer
Phase 3 trial initiation announced June 18, 2018.
Pyruvate kinase deficiency
Phase 3 initiated 2Q 2017.
Frontline Acute myeloid leukemia (AML) harboring an IDH1 mutation - cancer
Global Phase 3 study for AG-221 initiated October 2015. Continues to enroll as of January 2018.
Enasidenib (AG-221) - IDHENTIFY
Refractory Acute myeloid leukemia (AML) - cancer
Approval announced August 1, 2017.
IDHIFA (enasidenib) - AG-221
Advanced hematologic malignancies with an IDH2 mutation
Phase 3 initiated December 2016. Enrollment to be completed 1H 2019.
AG-120 Ivosidenib
IDH1 mutant positive cholangiocarcinoma - cancer
Phase 1 data at ASCO June 2018 noted CR rate was 24%.
AG-120 Ivosidenib
R/R Acute Myeloid Leukemia (AML)
Phase 1/2 updated data at ASCO June 2018. ORR of 78%, CR Rate of 44%.
Enasidenib or ivosidenib with VIDAZA
Frontline AML with IDH1 or IDH2 mutation
Phase 1 first data presented at ASH 2017 with updated data due at ASH 2018. Phase 3 trial to be initiated 4Q 2018.
Ivosidenib or enasidenib
Frontline AML with IDH1 or IDH2 mutation
Phase 1 dosing of first patient announced March 19, 2018.
Solid tumors
Phase 1 data presented at ASCO June 1, 2018. 1 minor response + 1 partial response out of 93 patients.

Latest News

  1. Benzinga's Daily Biotech Pulse: AbbVie Launches New Pediatric Humira, IPO Deluge Hits The Street
  2. Agios (AGIO) Initiates Phase III Study on PK Deficiency Drug
  3. Agios Announces Initiation of Global Phase 3 Trial (ACTIVATE) of AG-348 in Adults with Pyruvate Kinase Deficiency Who Are Not Regularly Transfused
  4. Agios Pharmaceuticals, Inc.Stock Is an Analyst Darling for Good Reason
  5. New Data from Phase 1 Study of Ivosidenib or Enasidenib in Combination with Azacitidine Demonstrate Robust Responses and a Well Tolerated Safety Profile in Newly Diagnosed IDHm AML Patients
  6. Agios Pharmaceuticals (AGIO) Up 13.4% Since Earnings Report: Can It Continue?
  7. Updated Data from Ivosidenib Phase 1 Dose-Escalation and Expansion Trial in IDH1m Relapsed or Refractory AML Continue to Show Durable Responses as a Single Agent
  8. Agios Presents Data from Phase 1 Dose-Escalation Study of AG-881 in Patients with IDH Mutant Positive Advanced Glioma and Other Solid Tumors
  9. Today's Research Reports on Trending Tickers: Tesaro and Agios Pharmaceuticals
  10. Benzinga's Daily Biotech Pulse: Organovo Falls On Earnings; Celgene Gets New CFO
  11. Investors Should Own Agios For 'The Next Several Years,' Analyst Says
  12. Agios Pharmaceuticals Has Emerged From a 2-Year Base Pattern
  13. Agios (AGIO) Progressing Well on Pipeline Amid Competition
  14. Market Trends Toward New Normal in Agios Pharmaceuticals, Corcept Therapeutics, Prestige Brand, Virtu Financial, Eagle Pharmaceuticals, and Century Aluminum — Emerging Consolidated Expectations, Analyst Ratings
  15. Agios to Present New Clinical Data from its IDH Programs at ASCO
  16. See what the IHS Markit Score report has to say about Agios Pharmaceuticals Inc.
  17. Agios (AGIO) Q1 Loss Wider than Expected, Revenues Miss
  18. Agios Pharmaceuticals: 1Q Earnings Snapshot
  19. Agios Provides Business Update on Discovery Research Strategy and Pipeline, Progress on Clinical Programs, Commercial Launch Preparations and Reports First Quarter 2018 Financial Results at Investor Day
  20. Is a Beat in the Cards for Agios (AGIO) in Q1 Earnings?